<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> is a type of <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> characterized by progressive <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> with worsening cytopenia and in a subset of patients, progression to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Published data in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> have shown that the development of <z:mp ids='MP_0000220'>monocytosis</z:mp> in the course of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> is associated with a poor prognosis </plain></SENT>
<SENT sid="2" pm="."><plain>A similar occurrence has been only sporadically reported in patients with primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Over a period of four years we identified 10 out of 237 cases of primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> who developed persistent absolute <z:mp ids='MP_0000220'>monocytosis</z:mp> (&gt;1 Ã— 10(9)/l) during the course of disease (5 men and 5 women; median age/range: 68 years/52-82) </plain></SENT>
<SENT sid="4" pm="."><plain><z:mp ids='MP_0000220'>Monocytosis</z:mp> developed at a median interval of 42 months from diagnosis (range: 1-180) and persisted for a median period of 23 months (range: 2-57) </plain></SENT>
<SENT sid="5" pm="."><plain>Five patients died after developing <z:mp ids='MP_0000220'>monocytosis</z:mp> (range: 20-188 months) and two experienced worsening disease and became transfusion dependent </plain></SENT>
<SENT sid="6" pm="."><plain><z:mp ids='MP_0000220'>Monocytosis</z:mp> was associated with increased white blood cells, decreased <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, decreased platelet count, and the presence of circulating blasts </plain></SENT>
<SENT sid="7" pm="."><plain>In three cases, bone marrow biopsies after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:mp ids='MP_0000220'>monocytosis</z:mp> showed marked myelomonocytic proliferation with morphological shifting from a typical primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> marrow appearance to aspects compatible with an overt 'secondary' <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Before the development of <z:mp ids='MP_0000220'>monocytosis</z:mp>, 5 of 10 patients carried the JAK2V617F mutation; five patients showed karyotypic alterations </plain></SENT>
<SENT sid="9" pm="."><plain>No change in JAK2 mutational status or cytogenetic evolution were associated with the development of <z:mp ids='MP_0000220'>monocytosis</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Four of nine patients analyzed showed KRAS mutation in codon 12 or 13 with low allele burden </plain></SENT>
<SENT sid="11" pm="."><plain>This is the first study correlating <z:mp ids='MP_0000220'>monocytosis</z:mp> developing in primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> patients with bone marrow <z:mp ids='MP_0000002'>morphology</z:mp>, laboratory data, molecular analysis and clinical follow-up </plain></SENT>
<SENT sid="12" pm="."><plain>Development of <z:mp ids='MP_0000220'>monocytosis</z:mp> in patients with established primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> is associated with rapid disease progression and these patients should be considered as a high-risk group associated with short survival </plain></SENT>
</text></document>